TITLE

Treating glucocorticoid-induced osteoporosis

AUTHOR(S)
Elliott, William T.
PUB. DATE
June 2009
SOURCE
Travel Medicine Advisor;Jun2009 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports on a study published in "Lancet," which suggests that a once a year infusion of zoledronic acid is as effective as daily risedronate for preventing and treating bone loss. The study involved 833 patients with glucocorticoid-induced osteoporosis subjected to randomized, double-blind, placebo-controlled non-inferiority methods. It concluded that a once a year infusion of zoledronic acid produced a more effective prevention and treatment of osteoporosis.
ACCESSION #
40397026

 

Related Articles

  • Protect your most beautiful asset. McCord, Holly; Hanlon, Toby // Prevention;May97, Vol. 49 Issue 5, p94 

    Announces ways to protect women's bones from Osteoporosis. Questions posed by 'Prevention'; Responses from endocrinologist John Bilezikian; The need for a bone-density test at the start of menopause; Advice from the National Osteoporosis Foundation; Baby-boomers and osteoporosis; Calcium...

  • 7 Supplements for Better Bones. Adderly, Brenda // Better Nutrition;Jul2000, Vol. 62 Issue 7, p72 

    Enumerates the seven necessary nutrients to maintain strong bones and prevent osteoporosis. Calcium; Nutrients that maximize calcium absorption; Boron; Manganese; Silicon; Methyl sulfonyl methane; Copper.

  • Boning up. Franklin, Deborah // Health (Time Inc. Health);Jul/Aug94, Vol. 8 Issue 4, p88 

    Focuses on the effectiveness of calcium, exercise and estrogen to lower the risk of osteoporosis. Precipitating factors for osteoporosis; Diagnosis; Types of exercise which help in building strong bones; Amount of calcium needed by the body; Amount of estrogen required to cut the risk of...

  • Once-a-year bone protection. Yeager, Selene // Prevention;Feb2007, Vol. 59 Issue 2, p42 

    The article looks at a new treatment for osteoporosis known as ReClast. The treatment requires an infusion once a year. A study found that women who received ReClast had a lower risk of spinal fracture and hip fracture than those who got a placebo. According to the article, ReClast's results are...

  • Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Steffensen, Linn H.; Jørgensen, Lone; Straume, Bjørn; Mellgren, Svein Ivar; Kampman, Margitta T. // Journal of Neurology;Sep2011, Vol. 258 Issue 9, p1624 

    Multiple sclerosis (MS) is a possible cause of secondary osteoporosis. In this phase II trial we assessed whether a weekly dose of 20,000 IU vitamin D prevents bone loss in ambulatory persons with MS age 18-50 years. ClinicalTrials.gov ID NCT00785473. All patients managed at the University...

  • Pharmacologic Prevention and Treatment Of Osteoporosis in Women. Capriotti, Teri // MEDSURG Nursing;Apr2000, Vol. 9 Issue 2, p86 

    Focuses on various pharmacologic treatments available to counteract osteoporosis in women. Characteristics of osteoporosis; Pharmacology involved in preserving bone strength; Recommended supplements for preventing the disease; Therapeutic use of estrogen; Information on selective estrogen...

  • Protect your bones.  // High Plains Journal;9/21/2015, Vol. 133 Issue 38, p15B 

    The article discusses the ways of protecting human bones from osteoporosis including through getting enough calcium and vitamin D, and eating more fruits and vegetables.

  • Action urged on osteoporosis.  // Australian Journal of Pharmacy;Apr2010, Vol. 91 Issue 1079, p28 

    The article focuses on the significant role of health professionals in detecting and preventing osteoporosis in Australia. The Access Economics report predicts that over three million people will have disease by 2020. It notes that 41% of those who received treatment fail to maintain their...

  • Effects of glucocorticoid treatment on bone strength. Manolides, Andrew S.; Cullen, Diane M.; Akhter, Mohammed P. // Journal of Bone & Mineral Metabolism;Sep2010, Vol. 28 Issue 5, p532 

    Glucocorticoids (GCs) are prescribed for the treatment of several diseases, but their long-term use causes osteoporosis. Current research suggests that GCs suppress the canonical Wnt/β pathway, resulting in decreased expression of critical bone proteins. This study examined how bone structure...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics